Society Corona - Stock Market thinktank

Welcome to our Community
Wanting to join the rest of our members? Feel free to Sign Up today.
Sign up
ThatOneDude

ThatOneDude

Commander in @Chief, Dick Army
First 100
Jan 14, 2015
35,390
34,114
Looks like we may make some money today gents. Lets do this.....choooo choooooo

 
ThatOneDude

ThatOneDude

Commander in @Chief, Dick Army
First 100
Jan 14, 2015
35,390
34,114
I'll tell your hwhat, not a bad start to friday.
Maybe if AER can get its fucking shit together I'll be all green.

 
ThatOneDude

ThatOneDude

Commander in @Chief, Dick Army
First 100
Jan 14, 2015
35,390
34,114
My kid is sleeping but i want to start yelling to my wife that we are about to be rich bitchhhhhhhhh
 
ThatOneDude

ThatOneDude

Commander in @Chief, Dick Army
First 100
Jan 14, 2015
35,390
34,114
AER is up over 1.50, hopefully today is the day they get their head out of their ass.
 
ThatOneDude

ThatOneDude

Commander in @Chief, Dick Army
First 100
Jan 14, 2015
35,390
34,114
Boeing is set to reopen next week. Could be good for people who hold that.
 
ThatOneDude

ThatOneDude

Commander in @Chief, Dick Army
First 100
Jan 14, 2015
35,390
34,114
Anyone who bought into GILD at open, Me, may be getting fucked by articles like this:
The Market Is Overreacting to Gilead's Coronavirus Drug Remdesivir, Analysts Say -- Barrons.com
9:43 am ET April 17, 2020 (Dow Jones) Print



By Josh Nathan-Kazis

Investors may be too enthusiastic about a scoop from the health-care news website STAT on a trial of Gilead Sciences' antiviral drug remdesivir in patients with severe Covid-19, analysts say.

Gilead (ticker: GILD) shares were up 10.6% shortly after the open on Friday, and had risen much further in trading after the close on Thursday. STAT reported Thursday evening that nearly all of the patients at one Chicago hospital participating in a Gilead-sponsored trial of remdesivir were discharged in less than a week.

The S&P 500 and other major stock indexes rallied in response to the news, as well as President Donald Trump's Thursday announcement of guidelines for the reopening of states' economies.

Investors are waiting on results of a handful of large, randomized trials of remdesivir, the first of which are expected any day. The STAT report isn't data from the trial, but rather a positive anecdote from one trial site. Yet the stock's moves were as dramatic as those analysts had expected might result from a positive trial readout.

"We would have thought that kind of reaction would have been reserved for positive clinical trials," wrote Cantor Fitzgerald analyst Alethia Young. She wrote two weeks ago that the results of a trial would likely move Gilead stock 10% to 15% in either direction.

Hints about remdesivir's efficacy have been coming in drips in recent days. On April 10, the New England Journal of Medicine published data from hospitalized Covid-19 patients given remdesivir on a compassionate-use basis that appeared to be positive.

Then, just days ago, Gilead was reported to have suspended a trial of remdesivir in China, which analysts took as a bad sign. The company said that it had struggled to find patients to enroll in the study.

The STAT report offers another positive data point in advance of actual trial results, but some analysts said Thursday night that the market was too enthusiastic. "While the article paints a pretty picture, we think the ensuing exuberance shows a lack of critical analysis," Baird analyst Brian Skorney wrote. "This is uncontrolled, anecdotal data, which often winds up not being confirmed in controlled studies"

A Raymond James note on Thursday night from analyst Steven Seedhouse said that the report had added "confusion," but said that if the results described in the article were reproducible, it would likely be enough for the Food and Drug Administration to give Gilead an emergency-use authorization allowing for remdesivir to be used to treat Covid-19.

Regardless of remdesivir's efficacy, analysts generally agree that it will have minimal commercial impact for Gilead. "We continue to see remdesivir as more impactful to GILD's image and enabling recognition of their strong commercial portfolio and pipeline optionality, more so than a materially monetizable nearterm driver," wrote RBC Capital Markets analyst Brian Abrahams.

Abrahams wrote that the key set of data on remdesivir will be the results of a Gilead-sponsored study of the drug in moderate cases, due in May.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com



(END) Dow Jones Newswires
Click to expand...
 
Hauler

Hauler

Been fallin so long it's like gravitys gone
Feb 3, 2016
47,666
59,557
ThatOneDude said:
I'll tell your hwhat, not a bad start to friday.
Maybe if AER can get its fucking shit together I'll be all green.

Click to expand...
AER is up 7.6% today.

That was one of the ones I grabbed a while back. Up 18% overall on that one.
 
Hauler

Hauler

Been fallin so long it's like gravitys gone
Feb 3, 2016
47,666
59,557
CNK might be in for a nice run if they start opening shit. Steady $30+ stock trading sub $15.

I already bought in at $10. Feeling good about that one.
 
Hauler

Hauler

Been fallin so long it's like gravitys gone
Feb 3, 2016
47,666
59,557
Holy shit at oil.
Showing UNDER $11 pre-market

Russia and Saudi have to be looking at each other like "Well that was fucking stupid"
 
You must log in or register to reply here.
Top Bottom